发明授权
- 专利标题: Nucleolar targeting of therapeutics against HIV
- 专利标题(中): 针对艾滋病毒治疗药物的核仁靶点
-
申请号: US12835333申请日: 2010-07-13
-
公开(公告)号: US08227442B2公开(公告)日: 2012-07-24
- 发明人: John J. Rossi , Alessandro Michienzi
- 申请人: John J. Rossi , Alessandro Michienzi
- 申请人地址: US CA Duarte
- 专利权人: City of Hope
- 当前专利权人: City of Hope
- 当前专利权人地址: US CA Duarte
- 代理机构: Rothwell, Figg, Ernst & Manbeck, P.C.
- 主分类号: C12N15/11
- IPC分类号: C12N15/11 ; C07H21/04
摘要:
The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it is likely that the nucleolus plays a critical role in Rev-mediated export of singly spliced and unspliced HIV-1 RNAs. As a test for trafficking of HIV-1 RNAs into the nucleolus, a hammerhead ribozyme which specifically cleaves HIV-1 RNA was joined to the U16 snoRNA resulting in accumulation of the ribozyme within nucleoli of human cells. Stably transduced human T-cells expressing this nucleolar localized ribozyme dramatically suppressed HIV-1 replication, confirming a possible trafficking of the HIV RNA through the nucleoli of human cells. In addition, a TAR element which binds Tat was joined to the U16 snoRNA, also resulting in localization in the nucleoli and inhibiting HIV replication.
公开/授权文献
- US20110046208A1 NUCLEOLAR TARGETING OF THERAPEUTICS AGAINST HIV 公开/授权日:2011-02-24
信息查询
IPC分类: